Every material Form 8-K NOVAVAX INC has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Novavax reported third-quarter 2026 total revenue of $68 million, down 3% from $70 million a year earlier, while its net loss narrowed to $31 million from $202 million. The company raised its full-year 2026 Adjusted Total Revenue guidance to $385 million to $415 million, up from $235 million to $275 million, mainly reflecting a $125 million Sanofi milestone earned in October 2026.
Q3 2026 total revenue was $68 million, versus $70 million in Q3 2025.
Q3 2026 net loss was $31 million, versus $202 million in Q3 2025.
Full-year 2026 Adjusted Total Revenue guidance raised to $385 million-$415 million from $235 million-$275 million.
Combined R&D and SG&A expense guidance narrowed to $375 million-$395 million from $370 million-$410 million.
Novavax said Sanofi dosed the fifth patient in a Phase 3 influenza-COVID-19 combination vaccine trial in the European Union on October 28, 2026, using Novavax's COVID-19 component. That dosing triggers a $125 million milestone payment under the companies' collaboration agreement, which Novavax expects to receive by the first quarter of 2027.
$125 million milestone payment from Sanofi triggered by dosing of the fifth patient on October 28, 2026
Payment expected by the first quarter of 2027
Additional eligible payments include a $75 million milestone on manufacturing technology transfer, anticipated mid-2027, and a $225 million milestone on a U.S. launch of a combination vaccine
CEO John C. Jacobs said the partnership has generated over $1 billion in revenue for Novavax to date
Novavax reported second quarter 2026 total revenue of $57 million, down 76% from $239 million a year earlier, when results included $202 million from a Nuvaxovid approval milestone and a Takeda amendment. The company posted a net loss of $53 million, or $0.32 per share, compared with net income of $107 million a year earlier. It raised its full-year 2026 adjusted revenue framework and lowered its combined R&D and SG&A expense guidance, so shareholders face a sharp revenue decline alongside higher revenue guidance and lower expense guidance.
Q2 2026 total revenue was $57 million vs $239 million in Q2 2025; Sanofi revenue fell to $36 million from $199 million
Net loss of $53 million ($0.32 per share) vs net income of $107 million in Q2 2025 (basic EPS $0.66)
Full-year 2026 Adjusted Total Revenue framework raised to $235 million-$275 million from $230 million-$270 million
Combined R&D and SG&A expense guidance lowered to $370 million-$410 million from $380 million-$420 million; cash was $724 million at June 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NOVAVAX INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →